Literature DB >> 21172379

Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen.

Alison L Every1, Andrew Stent, Margaret B Moloney, Garrett Z Ng, Caroline D Skene, Stirling J Edwards, Philip Sutton.   

Abstract

Helicobacter pylori, the major cause of gastric cancer, have mechanisms that allow colonization of the inhospitable gastric mucosa, including enzymes such as superoxide dismutase (SOD) which protect against reactive oxygen species. As SOD is essential for in vivo colonization, we theorized it might constitute a viable vaccine target. H. pylori SOD was expressed in E. coli and a purified recombinant protein used to vaccinate mice, prior to live H. pylori challenge. Partial protective immunity was induced, similar to that commonly observed with other antigens tested previously. This suggests SOD may have utility in a combination vaccine comprising several protective antigens.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172379     DOI: 10.1016/j.vaccine.2010.12.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

2.  Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease.

Authors:  Louise Baker; Andre M L Chitas; Carol A Hartley; Mauricio J C Coppo; Paola K Vaz; Andrew Stent; James R Gilkerson; Joanne M Devlin; Alison L Every
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

3.  A Novel Design of Multi-epitope Vaccine Against Helicobacter pylori by Immunoinformatics Approach.

Authors:  Junfei Ma; Jingxuan Qiu; Shuying Wang; Qianyu Ji; Dongpo Xu; Haiwang Wang; Zhiguang Wu; Qing Liu
Journal:  Int J Pept Res Ther       Date:  2021-01-02       Impact factor: 1.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.